Emerging Technologies for Assessing HER2 Amplification
Open Access
- 1 October 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 132 (4) , 539-548
Abstract
Patients with human epidermal growth factor receptor-2 (HER2)+ breast cancer are eligible for trastuzumab treatment; therefore, accurate assessment oKeywords
This publication has 60 references indexed in Scilit:
- Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 AmplificationClinical Cancer Research, 2007
- Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring studyBreast Cancer Research, 2007
- Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplificationBreast Cancer Research, 2007
- Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancerJournal of Clinical Pathology, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomasJournal of Clinical Pathology, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- c-erbB-2 DNA Amplification and mRNA Expression in Human Primary Breast Tumors and Its Relationship to Other Prognostic FactorsCancer Biotherapy, 1993
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987